Verzenio (abemaciclib) is a targeted cancer drug used to treat hormone receptor-positive, HER2-negative breast cancer. It’s approved for both early-stage breast cancer with a high risk of recurrence and advanced or metastatic breast cancer that has spread beyond the breast. It works by blocking specific proteins that drive cancer cell growth, and it’s taken as a pill twice daily, either alone or alongside hormone therapy.
How Verzenio Works
Cancer cells need to copy their DNA and divide to grow. A critical step in that process is the transition from the resting phase of the cell cycle into the phase where DNA is actively copied. Two proteins, called CDK4 and CDK6, act like switches that push cells through that transition. In hormone receptor-positive breast cancer, these switches are often stuck in the “on” position, fueling unchecked cell division.
Verzenio blocks both CDK4 and CDK6, effectively jamming those switches. When the drug is present, cancer cells stall before they can copy their DNA. With prolonged exposure, the stalled cells begin to age and die off rather than simply pausing. In lab studies, Verzenio is roughly 14 times more potent at blocking these targets than two other drugs in the same class (palbociclib and ribociclib), though potency in a lab dish doesn’t always translate neatly to clinical differences.
Early-Stage Breast Cancer After Surgery
Verzenio’s most notable role is as an “adjuvant” treatment, meaning it’s given after surgery to reduce the chance cancer comes back. This use is specifically for people whose breast cancer is hormone receptor-positive, HER2-negative, has spread to nearby lymph nodes, and carries a high risk of recurrence. High risk is defined as having four or more positive lymph nodes, or one to three positive lymph nodes combined with either a high tumor grade or a tumor 5 centimeters or larger. The tumor also needs a Ki-67 score of 20% or higher, a lab marker that reflects how quickly cancer cells are dividing.
In this setting, Verzenio is taken for two years alongside standard hormone therapy such as tamoxifen or an aromatase inhibitor. The large clinical trial behind this approval, called monarchE, followed patients for a median of about four and a half years. At the five-year mark, 83.6% of patients who took Verzenio plus hormone therapy were free of invasive disease, compared to 76.0% of those on hormone therapy alone. That 7.6 percentage-point difference represents a meaningful reduction in the risk of cancer returning.
Advanced or Metastatic Breast Cancer
When hormone receptor-positive, HER2-negative breast cancer has spread or can’t be surgically removed, Verzenio is approved in three distinct scenarios, each reflecting a different point in the treatment journey.
First-Line Treatment
For postmenopausal women and men who haven’t yet started treatment for advanced disease, Verzenio can be combined with an aromatase inhibitor as the initial therapy. In the MONARCH 3 trial, adding Verzenio to an aromatase inhibitor extended the time before cancer progressed by a median of 14.3 months compared to the aromatase inhibitor alone.
After Hormone Therapy Stops Working
If the cancer grows despite hormone therapy, Verzenio can be paired with fulvestrant (a different type of hormone-blocking injection). This combination gives patients another targeted option before moving to chemotherapy.
Standalone Treatment
For patients whose cancer has progressed through both prior hormone therapy and chemotherapy, Verzenio can be used on its own. This is the only CDK4/6 inhibitor approved as a single agent for breast cancer, which makes it a distinct option when combination approaches are no longer viable. The dose is higher in this setting: 200 mg twice daily, compared to 150 mg twice daily when used in combination with other drugs.
Common Side Effects
Diarrhea is by far the most common side effect. In clinical trials, it affected roughly 82% to 90% of patients depending on the study, though the majority of cases were mild to moderate. Severe diarrhea (grade 3) occurred in about 9% to 20% of patients, with higher rates seen at the higher single-agent dose. Diarrhea tends to be most frequent in the first month of treatment and often improves with dose adjustments or anti-diarrheal medications.
Low white blood cell counts (neutropenia) are the most common severe side effect in combination trials, which is why blood counts are monitored regularly during treatment. Other frequently reported side effects include nausea, fatigue, abdominal pain, and changes in liver function tests. Your oncology team will run blood work at regular intervals, particularly in the first several months, to catch any problems early and adjust the dose if needed.
What Treatment Looks Like Day to Day
Verzenio is a tablet taken by mouth twice a day, with or without food, at roughly the same times each day. Most people take one dose in the morning and one in the evening. Unlike some cancer treatments that follow an on-and-off cycle, Verzenio is taken continuously without scheduled breaks, though your doctor may temporarily pause or reduce the dose to manage side effects.
For early-stage breast cancer, the standard treatment course is two years. For advanced or metastatic disease, treatment typically continues for as long as it’s working and side effects remain manageable. Throughout treatment, you’ll have periodic lab work and check-ins to monitor how your body is responding.